Skip to main content

Dehydration

14
Pipeline Programs
8
Companies
14
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
14
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

Halozyme Therapeutics
HYDASEApproved
hyaluronidase
Halozyme Therapeutics
injection2005
Halozyme Therapeutics
HYLENEX RECOMBINANTApproved
hyaluronidase
Halozyme Therapeutics
Endoglycosidase [EPC]injection2005

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Baxter
BaxterCosta Rica - Cartago
8 programs
7
HylenexPhase 4
Oral rehydration fluidPhase 4
Subcutaneous HYLENEXPhase 4
hyaluronidasePhase 4
hylenex-facilitated subcutaneous Lactated Ringer's infusionPhase 4
+3 more programs
Halozyme Therapeutics
5 programs
5
Oral rehydration fluidPhase 41 trial
Subcutaneous HYLENEXPhase 41 trial
hyaluronidasePhase 41 trial
hylenex-facilitated subcutaneous Lactated Ringer's infusionPhase 41 trial
recombinant human hyaluronidasePhase 41 trial
Active Trials
NCT01120431Withdrawn0Est. May 2010
NCT01116102Terminated20Est. Jun 2010
NCT00477152Completed52Est. Jun 2008
+2 more trials
Baxter International
8 programs
Subcutaneous Recombinant Human Hyaluronidase: Workflow Analysis and Emergency Department DesignN/A1 trial
HylenexPHASE_41 trial
Oral rehydration fluidPHASE_4
Subcutaneous HYLENEXPHASE_4
hyaluronidasePHASE_4
+3 more programs
Active Trials
NCT01020513Withdrawn0Est. Feb 2011
NCT01139294Completed17Est. Nov 2011
NCT01234883Terminated100Est. Feb 2013
Abbott
AbbottABBOTT PARK, IL
2 programs
Oral Rehydration SolutionN/A1 trial
Oral Rehydration SolutionN/A1 trial
Active Trials
NCT06368765Terminated9Est. Oct 2024
NCT06130475Completed26Est. Dec 2024
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
Body Composition MonitoringN/A1 trial
Active Trials
NCT02655341UnknownEst. Jan 2018
Intelligent Therapeutics
1 program
DehydrationN/A1 trial
Active Trials
NCT01124903Completed31Est. Mar 2011
Innovation Pharmaceuticals
1 program
Reference Values and Determinants of Hydration in Children 3-13 yN/A1 trial
Active Trials
NCT02937038Terminated1,454Est. Jun 2021
Innate Pharma
Innate PharmaFrance - Marseille
1 program
WaterN/A1 trial
Active Trials
NCT07468539Completed17Est. May 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Baxter Internationalmultiple electrolyte solution
Halozyme TherapeuticsSubcutaneous HYLENEX
Halozyme TherapeuticsOral rehydration fluid
Baxter InternationalHylenex
Halozyme Therapeuticshylenex-facilitated subcutaneous Lactated Ringer's infusion
Halozyme Therapeuticsrecombinant human hyaluronidase
Halozyme Therapeuticshyaluronidase
Innate PharmaWater
AbbottOral Rehydration Solution
AbbottOral Rehydration Solution
Innovation PharmaceuticalsReference Values and Determinants of Hydration in Children 3-13 y
T-TherapeuticsBody Composition Monitoring
Baxter InternationalSubcutaneous Recombinant Human Hyaluronidase: Workflow Analysis and Emergency Department Design
Intelligent TherapeuticsDehydration

Clinical Trials (14)

Total enrollment: 1,974 patients across 14 trials

NCT01234883Baxter Internationalmultiple electrolyte solution

Intravenous (IV) Solutions for Dehydration in Children With Gastroenteritis

Start: Jun 2011Est. completion: Feb 2013100 patients
Phase 4Terminated
NCT01116102Halozyme TherapeuticsSubcutaneous HYLENEX

Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)

Start: May 2010Est. completion: Jun 201020 patients
Phase 4Terminated
NCT01120431Halozyme TherapeuticsOral rehydration fluid

Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus ORT for Dehydrated Children in the Emergency Department (ED)

Start: May 2010Est. completion: May 20100
Phase 4Withdrawn
NCT01139294Baxter InternationalHylenex

Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics

Start: Feb 2010Est. completion: Nov 201117 patients
Phase 4Completed
NCT00807885Halozyme Therapeuticshylenex-facilitated subcutaneous Lactated Ringer's infusion

Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase

Start: Dec 2008Est. completion: Jan 2009100 patients
Phase 4Completed
NCT00773175Halozyme Therapeuticsrecombinant human hyaluronidase

Subcutaneous Rehydration Compared to Intravenous Rehydration

Start: Oct 2008Est. completion: Dec 2009148 patients
Phase 4Completed
NCT00477152Halozyme Therapeuticshyaluronidase

Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase for Infants and Children

Start: Aug 2007Est. completion: Jun 200852 patients
Phase 4Completed
NCT07468539Innate PharmaWater

Post-exercise Rehydration: A Randomised Cross-over Trial Comparing a 100% Fruit Beverage, a Glucose-based Sports Drink, and Water

Start: Nov 2024Est. completion: May 202517 patients
N/ACompleted
NCT06368765AbbottOral Rehydration Solution

Oral Rehydration Solution and Dehydration Recovery

Start: Jul 2024Est. completion: Oct 20249 patients
N/ATerminated
NCT06130475AbbottOral Rehydration Solution

Oral Rehydration Solution in Healthy Adults

Start: Mar 2024Est. completion: Dec 202426 patients
N/ACompleted
NCT02937038Innovation PharmaceuticalsReference Values and Determinants of Hydration in Children 3-13 y

Reference Values and Determinants of Hydration in Children 3-13 y

Start: Jun 2016Est. completion: Jun 20211,454 patients
N/ATerminated
NCT02655341T-TherapeuticsBody Composition Monitoring

Hydration Status Assessment Through Body Composition Monitoring in Patients With Acute Myocardial Infarction

Start: Jan 2016Est. completion: Jan 2018
N/AUnknown
NCT01020513Baxter InternationalSubcutaneous Recombinant Human Hyaluronidase: Workflow Analysis and Emergency Department Design

Subcutaneous Recombinant Human Hyaluronidase: Workflow Analysis and Emergency Department Design

Start: Nov 2010Est. completion: Feb 20110
N/AWithdrawn
NCT01124903Intelligent TherapeuticsDehydration

Human Hydration Status Monitoring

Start: Jan 2009Est. completion: Mar 201131 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.